Allegheny General Hospital, part of Allegheny Health Network, is the first hospital in the western Pennsylvania region to offer Lemtrada, a new treatment for multiple sclerosis which is providing hope for patients who haven’t had success with other MS drugs.
PITTSBURGH, Pa., May 8, 2015 (GLOBE NEWSWIRE) — via PRWEB – Physicians at Allegheny General Hospital (AGH), part of Allegheny Health Network, are offering a new treatment for patients with relapsing multiple sclerosis (MS).AGH is the first hospital in the western Pennsylvania region to offer the treatment, which is providing new hope for patients who haven’t had success with other MS drugs.
FDA approved in fall of 2014, Lemtrada is an infusible medication designed to reduce flare ups in patients with relapsing MS and slow the progression of the disease.
“It’s wonderful to have a new option for patients with aggressive MS who have tried various medications and still haven’t achieved remission,” said Thomas Scott, MD, director of the Multiple Sclerosis Treatment Center at Allegheny General Hospital.
MS is a chronic disease that affects the nervous system by damaging myelin, the protective coating covering nerves. People with MS experience progressive deterioration of myelin which may result in pain, tingling or burning sensations, vision loss, mobility difficulties, muscle spasms or stiffness, difficulty with balance and speech and impaired memory and cognitive function.
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews